{"id":1466,"date":"2025-10-10T11:55:50","date_gmt":"2025-10-10T11:55:50","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=1466"},"modified":"2025-10-10T11:55:50","modified_gmt":"2025-10-10T11:55:50","slug":"cadenza-bio-announces-peer-reviewed-study-showing-oral-brain-penetrant-er%ce%b2-ligands-drive-remyelination-and-functional-recovery-in-ms-models","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/cadenza-bio-announces-peer-reviewed-study-showing-oral-brain-penetrant-er%ce%b2-ligands-drive-remyelination-and-functional-recovery-in-ms-models\/","title":{"rendered":"Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ER\u03b2 Ligands Drive Remyelination and Functional Recovery in MS Models"},"content":{"rendered":"

Published in Scientific Reports, a Nature Portfolio journal, the study details dual acting small molecules that restore myelin, modulate inflammation, and improve visual pathway function in preclinical MS models.<\/i><\/p>\n

\n

OKLAHOMA CITY<\/span>, Oct. 9, 2025<\/span> \/PRNewswire\/ — Cadenza Bio, Inc. today announced that a collaborative study, “Chloroindazole based Estrogen Receptor \u03b2 ligands with favorable pharmacokinetics promote functional remyelination and visual recovery,” has been published in Scientific Reports (https:\/\/www.nature.com\/articles\/s41598-025-20254-9<\/a>).<\/p>\n

The work, authored by scientists from the University of California Riverside, University of Illinois Urbana-Champaign, The Scripps Research Institute, and Cadenza Bio, and supported by the National Multiple Sclerosis Society’s Fast Forward commercial funding program, reports that two ER\u03b2 selective small molecules, K102 and K110, repair myelin and improve function in established mouse models of multiple sclerosis (MS), with pharmacokinetics suitable for oral dosing and central nervous system exposure.<\/p>\n

While most current MS therapies focus on reducing inflammation, few address the critical need for myelin repair or provide meaningful recovery. New preclinical results demonstrate that Cadenza Bio’s lead compounds, K102 and K110, deliver dual benefits, enhancing remyelination and modulating immune activity, with functional recovery observed in visual pathway measures routinely used in human MS studies.<\/p>\n

“Our findings demonstrate that ER\u03b2 ligand treatment promotes neuroprotection and enhances visual pathway function, as assessed by non-invasive measures such as OCT, ERG, and VEP in a mouse model of MS,” said Dr. Seema Tiwari-Woodruff, Corresponding Author and Scientific Founder of Cadenza Bio. “These measures are particularly valuable because they can also be applied non-invasively in patients, allowing direct translation into clinical trials.”<\/p>\n

Both compounds, K102 and K110, were well tolerated and highly selective for ER\u03b2, with no ER\u03b1-linked safety concerns observed. In addition, K102 promoted oligodendrocyte maturation in human iPSC-derived cells, reinforcing translational relevance.<\/p>\n

Study highlights (Preclinical)<\/b><\/p>\n